Financial & Tax Architects LLC Has $8.24 Million Holdings in Johnson & Johnson $JNJ

Key Points

• Financial & Tax Architects LLC cut its Johnson & Johnson stake by 11.5% in Q4 to 39,835 shares worth $8.244 million, which is about 1.9% of the firm's holdings and its 13th largest position.
• Analyst sentiment is bullish: Citigroup lifted its price target to $285 and maintained a Buy, and the consensus rating is a "Moderate Buy" with an average target of $237.57 after multiple firms raised targets or kept Buy calls.
• Company results and insider activity: J&J reported Q4 EPS of $2.46 on $24.28 billion in revenue and has a market cap of $580.5 billion (P/E 21.8), while insiders sold about 30,142 shares (~$7.36 million) in the past 90 days.

Financial & Tax Architects LLC lessened its position in Johnson & Johnson (NYSE:JNJ - Free Report) by 11.5% in the fourth quarter, according to its most recent disclosure with the SEC. The firm owned 39,835 shares of the company's stock after selling 5,173 shares during the period. Johnson & Johnson makes up about 1.9% of Financial & Tax Architects LLC's holdings, making the stock its 13th largest position. Financial & Tax Architects LLC's holdings in Johnson & Johnson were worth $8,244,000 at the end of the most recent reporting period.

A number of other hedge funds have also recently added to or reduced their stakes in the company. Wellington Management Group LLP boosted its position in shares of Johnson & Johnson by 3.8% during the third quarter. Wellington Management Group LLP now owns 25,832,777 shares of the company's stock valued at $4,789,914,000 after buying an additional 956,239 shares during the last quarter. Bank of New York Mellon Corp boosted its position in shares of Johnson & Johnson by 3.5% during the third quarter. Bank of New York Mellon Corp now owns 24,637,649 shares of the company's stock valued at $4,568,313,000 after buying an additional 835,146 shares during the last quarter. Legal & General Group Plc boosted its position in shares of Johnson & Johnson by 2.8% during the third quarter. Legal & General Group Plc now owns 19,450,064 shares of the company's stock valued at $3,606,431,000 after buying an additional 532,790 shares during the last quarter. Amundi boosted its position in shares of Johnson & Johnson by 19.3% during the third quarter. Amundi now owns 13,354,936 shares of the company's stock valued at $2,512,719,000 after buying an additional 2,163,838 shares during the last quarter. Finally, Raymond James Financial Inc. boosted its position in shares of Johnson & Johnson by 7.3% during the third quarter. Raymond James Financial Inc. now owns 10,137,651 shares of the company's stock valued at $1,879,718,000 after buying an additional 690,887 shares during the last quarter. Institutional investors and hedge funds own 69.55% of the company's stock.

Johnson & Johnson Stock Performance

NYSE:JNJ opened at $241.01 on Thursday. The company has a debt-to-equity ratio of 0.48, a current ratio of 1.03 and a quick ratio of 0.77. The business has a fifty day simple moving average of $240.79 and a two-hundred day simple moving average of $214.35. Johnson & Johnson has a 1 year low of $141.50 and a 1 year high of $251.71. The company has a market capitalization of $580.51 billion, a P/E ratio of 21.81, a P/E/G ratio of 2.41 and a beta of 0.34.

Johnson & Johnson (NYSE:JNJ - Get Free Report) last announced its quarterly earnings results on Saturday, January 31st. The company reported $2.46 earnings per share for the quarter. The company had revenue of $24.28 billion during the quarter. Johnson & Johnson had a return on equity of 33.04% and a net margin of 28.46%. On average, analysts expect that Johnson & Johnson will post 10.58 earnings per share for the current year.

Trending Headlines about Johnson & Johnson

Here are the key news stories impacting Johnson & Johnson this week:

• Positive Sentiment: Big analyst bullishness — Citigroup raised its price target to $285 and maintained a Buy, signaling a material upside to consensus; Guggenheim and TD Cowen also have Buy calls and lifted targets, supporting near-term demand. Citigroup raises price target to $285
• Positive Sentiment: New/maintained buy coverage from TD Cowen and supportive analyst commentary highlight J&J’s diversified pipeline and attractive risk/reward into earnings. TD Cowen / TipRanks coverage
• Positive Sentiment: Regulatory / product catalyst — J&J launched its next‑gen Varipulse Pro PFA catheter in Europe (CE mark), which could support device revenue growth in electrophysiology. Varipulse Pro launch in Europe
• Positive Sentiment: Specialty therapy wins — permanent U.S. reimbursement code for bladder cancer therapy INLEXZO and distribution deals (e.g., SIRTURO in Japan) reduce commercialization risk and boost revenue visibility in niche franchises. Johnson & Johnson updates key specialty therapies
• Neutral Sentiment: Media/analyst pieces are bullish ahead of Q1 — Barron's and other outlets recommend buying into the earnings run-up, which supports momentum but also raises expectations risk. Barron's: Buy ahead of earnings
• Neutral Sentiment: Mixed market commentary — coverage noting the stock “increases yet falls behind the market” and inclusion on low‑volatility/blue‑chip lists boost interest but are not direct fundamental drivers. Zacks: Increases yet falls behind market

Insider Activity

In other news, EVP Timothy Schmid sold 1,322 shares of Johnson & Johnson stock in a transaction dated Friday, February 20th. The stock was sold at an average price of $245.66, for a total transaction of $324,762.52. Following the completion of the sale, the executive vice president owned 25,447 shares in the company, valued at approximately $6,251,310.02. This trade represents a 4.94% decrease in their position. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, EVP Vanessa Broadhurst sold 6,197 shares of Johnson & Johnson stock in a transaction dated Tuesday, February 17th. The shares were sold at an average price of $243.39, for a total value of $1,508,287.83. Following the sale, the executive vice president owned 23,003 shares of the company's stock, valued at approximately $5,598,700.17. This trade represents a 21.22% decrease in their position. The SEC filing for this sale provides additional information. In the last ninety days, insiders sold 30,142 shares of company stock worth $7,360,528. Insiders own 0.16% of the company's stock.

Analyst Upgrades and Downgrades

JNJ has been the topic of a number of recent analyst reports. Loop Capital set a $220.00 price target on Johnson & Johnson in a report on Tuesday, January 27th. UBS Group reiterated a "buy" rating on shares of Johnson & Johnson in a report on Monday, January 5th. Scotiabank reiterated an "outperform" rating on shares of Johnson & Johnson in a report on Thursday, January 22nd. Citigroup lifted their price target on Johnson & Johnson from $274.00 to $285.00 and gave the stock a "buy" rating in a report on Tuesday. Finally, JPMorgan Chase & Co. lifted their price target on Johnson & Johnson from $225.00 to $250.00 and gave the stock a "neutral" rating in a report on Thursday, March 5th. One investment analyst has rated the stock with a Strong Buy rating, seventeen have given a Buy rating and nine have given a Hold rating to the company's stock. According to MarketBeat, the company currently has an average rating of "Moderate Buy" and a consensus target price of $237.57.

Johnson & Johnson Company Profile

Johnson & Johnson is a multinational healthcare company headquartered in New Brunswick, New Jersey, that develops, manufactures and markets a broad range of products across pharmaceuticals, medical devices and previously consumer health. Founded in 1886 by the Johnson family, the company has grown into a global healthcare organization with operations and sales in many countries around the world.

The company's pharmaceuticals business, organized largely under its Janssen research and development organization, focuses on prescription medicines across therapeutic areas such as immunology, infectious disease, oncology and neuroscience.

Want to see what other hedge funds are holding JNJ? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Johnson & Johnson (NYSE:JNJ - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.